Semaglutide

Semaglutide is a long-acting analogue of human glucagon-like peptide-1 (GLP-1) with 94% sequence homology to the native hormone. Research demonstrates that its structural modification—specifically, the addition of a C-18 fatty diacid chain—facilitates high-affinity binding to serum albumin, thereby extending its half-life and resistance to DPP-4 degradation. It functions as a potent GLP-1 receptor agonist to stimulate glucose-dependent insulin secretion and suppress glucagon release, serving as a primary subject for studies on glycemic control, weight management, and cardiovascular risk reduction.

For research use only. Not for human consumption.

References:
Lau J et al., J Med Chem, 2015 58(18):7370–7380
Marso SP et al., N Engl J Med, 2016 375(19):1834–1844
Wilding JPH et al., N Engl J Med, 2021 384(11):989–1002